Makes exon-skipping drugs and Elevidys gene therapy for Duchenne muscular dystrophy, a rare genetic disease.
Makes exon-skipping drugs and Elevidys gene therapy for Duchenne muscular dystrophy, a rare genetic disease.
Earns from selling a handful of Duchenne drugs, mostly in the US to patients who need them for life. The older exon-skipping injections give steady sales, while Elevidys, a one-time gene therapy, is lumpier. Roche holds rights to market Elevidys outside the US.
Moat: narrow (IP / patents, regulatory licence). First approved DMD gene therapy and multiple exon-skipping exclusivities are hard to replicate quickly.
Headquarters: Cambridge, Massachusetts, US · Founded: 1980 · Employees: 835
Size Sarepta Therapeutics (SRPT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.56B, the 1950th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.53 on 18 Nov 2026.
Performance Over six months the shares fell 15.1%, against -7.7% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 18.9% over the last twelve months (peer median +6.8%); the operating margin is -0.4% (peer median 12.0%).
Valuation It trades at 0.9× enterprise value to sales against a peer median of 4.5× (cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is -39 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.0 points below its cost of capital (6.6% WACC).
Credit Sarepta Therapeutics has 2 bonds outstanding ($1.03B).
Short interest Short interest is 18.0% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.96B | $2.20B | $1.90B | $1.24B | $933M |
| Revenue growth | — | +16% | +53% | +33% | — |
| Gross profit | $1.07B | $1.31B | $1.55B | $1.05B | $751M |
| EBITDA | $40.9M | -$599M | $272M | -$209M | -$476M |
| Net income | -$115M | -$713M | $235M | -$536M | -$703M |
| Free cash flow | $172M | -$325M | -$343M | -$577M | -$356M |
| Capital expenditure | $13.5M | $110M | $147M | $87.3M | $30.8M |
| Total debt | $1.05B | $1.04B | $1.34B | $1.40B | $1.62B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics SRPT | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
| Solid Biosciences SLDB | $709M | -2% | n/a | n/a | n/a | n/a |
| PTC Therapeutics PTCT | $5.03B | -15% | -35% | 22% | 3.1× | 6.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRPT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.2% | -4.6% | lowest of 21 |
| 6-month return | -15.1% | -7.7% | 7th lowest of 20 |
| Distance from 52-week high | -41.1% | -32.4% | 7th lowest of 21 |
| Revenue growth (TTM) | -18.9% | +6.8% | 3rd lowest of 20 |
| Operating margin | -0.4% | 12.0% | 3rd lowest of 20 |
| EV / Sales | 0.9× | 4.5× | cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -6.8% | 12.8% | 2nd least demanding of 14 |
| Growth delivered (Del g) | +32.4% | +1.9% | highest of 14 |
| Hurdle (Req g minus delivered) | -39.2 pp | +7.6 pp | least demanding of 14 |
| ROIC minus cost of capital | -7.0 pp | +1.2 pp | 6th lowest of 21 |
| Net debt / EBITDA | 4.3× | 0.1× | most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | 0.9× | -6.8% | +32.4% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 2.5× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 4.5× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 2.0× | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 1.4× | -6.1% | +1.9% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 1.2× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 5.2× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 9.8× | 31.1% | -15.1% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | 3.5× | -4.9% | +0.2% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 7.2× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | 46.5× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | 12.2× | 33.0% | +0.9% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | 17.0× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 8.9× | 36.3% | +16.6% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 2.2× | -14.9% | +13.5% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 8.9× | 18.4% | +10.8% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 3.1× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 1.4× | -6.4% | +12.7% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |
Sarepta Therapeutics has 2 bonds outstanding with $1.03B face value.